Valuation: Valneva SE

Market Cap 53Cr 61Cr 50Cr 46Cr 85Cr 5.84TCr 86Cr 600.6Cr 231.77Cr 2.97TCr 228.76Cr 223.68Cr 9.56TCr P/E 2026 *
-6.43x
P/E 2027 * 10.1x
Enterprise Value 66Cr 76Cr 63Cr 57Cr 106.79Cr 7.31TCr 107.23Cr 751.84Cr 290.13Cr 3.72TCr 286.36Cr 280Cr 12TCr EV / Sales 2026 *
4.4x
EV / Sales 2027 * 2.09x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
1 day-1.86%
1 week-3.35%
Current month+3.40%
1 month-8.85%
3 months+20.22%
6 months-40.73%
Current year-24.69%
1 week 2.8
Extreme 2.8
2.9
1 month 2.62
Extreme 2.62
3.14
Current year 2.03
Extreme 2.033
5.15
1 year 2.03
Extreme 2.033
5.34
3 years 1.73
Extreme 1.726
7.17
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Date Insider Type Main position Quantity % Market Cap. Importance
27/01/26 Sell

Chief Technology Officer

11,800 0.0069%
26/01/26 Sell

Chief Financial Officer

11,800 0.0069%
19/01/26 Exercice

Chief Technology Officer

82,899 0.0482%
Change 5-day change 1-year change 3-year change Capi.($)
-1.86%-3.35%-33.33%-55.54% 62Cr
+0.11%+1.98%-0.04%+9.69% 4.62TCr
-1.12%+3.54%+42.71%+25.84% 4.43TCr
-3.04%-6.10%+335.86%+501.23% 4.22TCr
-0.74%+2.64%+5.61%+75.14% 4.02TCr
-0.50%-0.77%+11.86%+40.41% 2.98TCr
-0.46%+5.00%+23.00%+118.70% 1.72TCr
-0.97%-9.38% - - 1.57TCr
-0.57%+7.78%+21.76%+38.08% 1.53TCr
-3.28%-0.95%-6.34%-37.29% 1.31TCr
Average -1.25%+1.35%+44.57%+79.58% 2.65TCr
Weighted average by Cap. -1.12%+1.63%+69.38%+116.79%

Financials

2026 *2027 *
Net sales 15Cr 17Cr 14Cr 13Cr 24Cr 1.66TCr 24Cr 170.79Cr 66Cr 844.81Cr 65Cr 64Cr 2.72TCr 28Cr 32Cr 27Cr 24Cr 46Cr 3.12TCr 46Cr 320.5Cr 123.68Cr 1.59TCr 122.07Cr 119.36Cr 5.1TCr
Net income -8.11Cr -9.3Cr -7.66Cr -6.96Cr -13Cr -892.59Cr -13Cr -92Cr -35Cr -453.8Cr -35Cr -34Cr -1.46TCr 5.31Cr 6.09Cr 5.01Cr 4.55Cr 8.53Cr 584.01Cr 8.56Cr 60Cr 23Cr 296.92Cr 23Cr 22Cr 955.37Cr
Net Debt 13Cr 15Cr 13Cr 11Cr 21Cr 1.47TCr 22Cr 151.24Cr 58Cr 748.09Cr 58Cr 56Cr 2.41TCr 6.25Cr 7.16Cr 5.9Cr 5.36Cr 10Cr 687.49Cr 10Cr 71Cr 27Cr 349.53Cr 27Cr 26Cr 1.12TCr
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
620
Date Price Change Volume
18/26/18 2.800 -1.86% 2,50,297
17/26/17 €2.853 -0.24% 2,23,413
16/26/16 €2.860 +1.38% 2,08,710
15/26/15 €2.821 -1.91% 3,58,624
14/26/14 €2.876 -0.42% 2,02,543
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.800EUR
Average target price
6.193EUR
Spread / Average Target
+121.17%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!